• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up.草药-矿物阿育吠陀疗法治疗一名二次复发的高危急性早幼粒细胞白血病患者:12年随访
J Ayurveda Integr Med. 2010 Jul;1(3):215-8. doi: 10.4103/0975-9476.72618.
2
Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy.采用阿育吠陀疗法治疗复发性未分化急性髓系白血病(AML-M0)。
Int J Ayurveda Res. 2011 Jan;2(1):56-9. doi: 10.4103/0974-7788.83184.
3
Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.急性早幼粒细胞白血病:全反式维甲酸(ATRA)联合化疗优于单纯使用ATRA。
Am J Hematol. 1999 Feb;60(2):87-93. doi: 10.1002/(sici)1096-8652(199902)60:2<87::aid-ajh1>3.0.co;2-5.
4
[Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].[全反式维甲酸对新诊断急性早幼粒细胞白血病的疗效:我们的经验]
Srp Arh Celok Lek. 1995 Nov-Dec;123(11-12):279-85.
5
[Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].[急性髓系白血病患者睾丸复发后接受大剂量白消安、依托泊苷和阿糖胞苷治疗后的第二次骨髓移植]
Rinsho Ketsueki. 1992 Mar;33(3):338-42.
6
Management of acute promyelocytic leukemia relapse in the ATRA era.全反式维甲酸时代急性早幼粒细胞白血病复发的管理
Haematologica. 1998 Aug;83(8):714-7.
7
[Complete remission induced by combined treatment with all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) in a patient with relapsed acute promyelocytic leukemia].全反式维甲酸(ATRA)与粒细胞集落刺激因子(G-CSF)联合治疗使一名复发急性早幼粒细胞白血病患者达到完全缓解
Rinsho Ketsueki. 1994 Nov;35(11):1315-21.
8
[Relapse of gingival tumor during hematological remission in acute promyelocytic leukemia].[急性早幼粒细胞白血病血液学缓解期牙龈肿瘤复发]
Rinsho Ketsueki. 1989 Nov;30(11):2020-3.
9
All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.全反式维甲酸与化疗联合治疗急性早幼粒细胞白血病
Indian J Cancer. 2004 Jul-Sep;41(3):125-8.
10
Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy.近年来难治性及复发性急性早幼粒细胞白血病预后的改善:全反式维甲酸治疗的作用
Ann Hematol. 1997 Nov-Dec;75(5-6):195-200. doi: 10.1007/s002770050342.

引用本文的文献

1
Linking Ayurveda and Western medicine by integrative analysis.通过综合分析将阿育吠陀医学与西医联系起来。
J Ayurveda Integr Med. 2013 Apr;4(2):117-9. doi: 10.4103/0975-9476.113882.
2
Ayurveda GCP Guidelines: Need for freedom from RCT ascendancy in favor of whole system approach.阿育吠陀药物临床试验质量管理规范指南:摆脱随机对照试验主导地位转而支持整体系统方法的必要性。
J Ayurveda Integr Med. 2011 Jan;2(1):1-4. doi: 10.4103/0975-9476.78175.

本文引用的文献

1
Tackling the cancer Tsunami.应对癌症海啸。
Indian J Cancer. 2009 Jan-Mar;46(1):1-4. doi: 10.4103/0019-509x.48588.
2
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.急性早幼粒细胞白血病的管理:代表欧洲白血病网的专家小组建议
Blood. 2009 Feb 26;113(9):1875-91. doi: 10.1182/blood-2008-04-150250. Epub 2008 Sep 23.
3
Does acute promyelocytic leukemia in Indian patients have biology different from the West?印度患者的急性早幼粒细胞白血病生物学特性与西方患者是否不同?
Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):437-9. doi: 10.4103/0377-4929.42555.
4
Acute promyelocytic leukemia: recent advances in diagnosis and management.急性早幼粒细胞白血病:诊断与治疗的最新进展
Semin Oncol. 2008 Aug;35(4):401-9. doi: 10.1053/j.seminoncol.2008.04.010.
5
Treatment of relapsed or refractory acute promyelocytic leukemia.复发或难治性急性早幼粒细胞白血病的治疗。
Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65. doi: 10.1016/j.beha.2006.11.002.
6
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.三氧化二砷在一名急性早幼粒细胞白血病(APL)患者中的临床药代动力学研究:血清和尿液中砷代谢物的形态分析
Biol Pharm Bull. 2006 May;29(5):1022-7. doi: 10.1248/bpb.29.1022.
7
Patterns and perceptions of complementary and alternative medicine (CAM) among leukaemia patients visiting haematology clinic of a north Indian tertiary care hospital.印度北部一家三级护理医院血液科门诊白血病患者对补充和替代医学(CAM)的使用模式及认知情况
Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):671-6. doi: 10.1002/pds.782.
8
Prognostic factors in acute myelogenous leukemia.急性髓系白血病的预后因素
Leukemia. 2001 Apr;15(4):670-2. doi: 10.1038/sj.leu.2402057.
9
A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.一种简单、可靠、经过验证且具有高度预测性的指数,用于确定源自医学研究理事会(MRC)AML 10试验的急性髓系白血病的风险导向治疗。英国医学研究理事会成人及儿童白血病工作组。
Br J Haematol. 1999 Oct;107(1):69-79. doi: 10.1046/j.1365-2141.1999.01684.x.

草药-矿物阿育吠陀疗法治疗一名二次复发的高危急性早幼粒细胞白血病患者:12年随访

Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up.

作者信息

Prakash Balendu, Parikh Purvish M, Pal Sanjoy K

机构信息

V C P Cancer Research Foundation (Scientific & Industrial Research Organization), Dehradun, India.

出版信息

J Ayurveda Integr Med. 2010 Jul;1(3):215-8. doi: 10.4103/0975-9476.72618.

DOI:10.4103/0975-9476.72618
PMID:21547051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3087364/
Abstract

A 47 year old diabetic male patient was diagnosed and treated for high risk AML-M3 at Tata Memorial Hospital (BJ 17572), Mumbai in September 1995. His bone marrow aspiration cytology indicated 96% promyelocytes with abnormal forms, absence of lymphocytic series and myeloperoxide test 100% positive. Initially treated with ATRA, he achieved hematological remission on day 60, but cytogenetically the disease persisted. The patient received induction and consolidated chemotherapy with Daunorubicin and Cytarabine combination from 12.01.96 to 14.05.96, following which he achieved remission. However, his disease relapsed in February 97. The patient was given two cycles of chemotherapy with Idarubicine and Etoposide, after which he achieved remission. His disease again relapsed in December 97. The patient then refused more chemotherapy and volunteered for a pilot Ayurvedic study conducted by the Central Council for Research in Ayurveda and Siddha, New Delhi. The patient was treated with a proprietary Ayurvedic medicine Navajeevan, Kamadudha Rasa and Keharuba Pisti for one year. For the subsequent 5 years the patient received three months of intermittent Ayurvedic treatment every year. The patient achieved complete disease remission with the alternative treatment without any adverse side effects. The patient has so far completed 13 years of survival after the start of Ayurvedic therapy.

摘要

一名47岁的男性糖尿病患者于1995年9月在孟买的塔塔纪念医院(BJ 17572)被诊断为高危急性早幼粒细胞白血病(AML-M3)并接受治疗。他的骨髓穿刺细胞学检查显示96%的早幼粒细胞形态异常,淋巴细胞系列缺失,髓过氧化物酶试验100%阳性。最初接受全反式维甲酸(ATRA)治疗,他在第60天实现了血液学缓解,但细胞遗传学上疾病仍持续存在。该患者于1996年1月12日至1996年5月14日接受了柔红霉素和阿糖胞苷联合诱导及巩固化疗,之后实现缓解。然而,他的疾病在1997年2月复发。该患者接受了两个疗程的伊达比星和依托泊苷化疗,之后实现缓解。他的疾病在1997年12月再次复发。然后该患者拒绝了更多化疗,并自愿参加了由新德里阿育吠陀和悉达研究中央理事会开展的一项阿育吠陀试点研究。该患者用一种专利阿育吠陀药物Navajeevan、Kamadudha Rasa和Keharuba Pisti治疗了一年。在随后的5年里,该患者每年接受3个月的间歇性阿育吠陀治疗。通过替代治疗,该患者实现了疾病完全缓解,且没有任何不良副作用。到目前为止,该患者自阿育吠陀治疗开始后已存活13年。